Eli Lilly Archives

News and Trends 13 Feb 2018

Watch Out Eli Lilly: Novo’s Diabetes Drug Ozempic Gets European Approval

Update (13/02/2018): The European Commission has given Novo Nordisk a market authorization for Ozempic (semaglutide), bringing the competition for Eli Lilly’s Trulicity over to Europe. Eli Lilly executives have said that they are not worried by Novo’s competition, and keep confident on the performance of Trulicity, which now tops 40% of the market share of diabetes drugs belonging […]

February 13, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 18 Oct 2017

Eli Lilly Offers German Biotech up to €1.5Bn to Develop mRNA Cancer Vaccines

CureVac will be working with pharma giant Eli Lilly in the development of up to five cancer vaccines based on mRNA technology. Eli Lilly will pay CureVac $50M (€43M) upfront and invest €45M in equity to kick off a collaboration for the development and commercialization of up to five mRNA vaccines for cancer. CureVac could receive up […]

October 18, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Eli Lilly Topas Therapeutics Autoimmune Disease

News and Trends 22 Aug 2017

Eli Lilly Partners with German Biotech Against Autoimmune Disease

Topas Therapeutics has signed a multi-year agreement with Eli Lilly to develop drug candidates for antigen-specific immunotherapy. The young Topas Therapeutics, a spin off from Evotec launched just last year, has managed to sign a research collaboration deal with big pharma Eli Lilly. The partners will work together on selecting external antigens that induce inflammation and autoimmune disease […]

August 22, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Novo Nordisk Semaglutide GLP 1 receptor agonist type 2 diabetes Eli Lilly Trulicity dulaglutide

More News! 18 Aug 2017

Novo Nordisk’s New Type 2 Diabetes Drug Outperforms Eli Lilly’s

Novo Nordisk has reported Phase III data that reveal its candidate semaglutide improved glucose control and weight loss in type 2 diabetes when compared with Eli Lilly’s dulaglutide. The results of the SUSTAIN 7 trial comparing the efficacy of Novo Nordisk’s semaglutide with Eli Lilly’s Trulicity (dulaglutide), already in the market, have revealed that Novo’s […]

August 18, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 12 Jun 2017

German Biotech Unveils Positive Phase II Results for Alzheimer’s

Probiodrug has disclosed encouraging results of its latest Phase IIa trial to assess its lead candidate PQ912 in patients with early Alzheimer’s Disease. The German biotech Probiodrug is pioneering new approaches to eliminate pyroglutamate (pGlu)-Abeta, a peptide that has been linked to the formation of toxic oligomers involved in Alzheimer’s disease. Now, the biotech came out […]

June 12, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 27 Jan 2017

Bad News for Diabetics: Eli Lilly Abandons French Ultra-Rapid Insulin

Eli Lilly has decided to terminate its partnership with Adocia for the development of BioChaperone Lispro, an ultra-rapid insulin for diabetes. Despite results from 6 clinical studies indicating that Adocia’s ultra-rapid insulin performs better than Eli Lilly’s Humalog, the big American pharma has decided to terminate its collaboration with the French biotech. As part of this […]

January 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 Dec 2016

The 8 Biggest Biotech Medical Fails of 2016 in Europe

Although 2016 has brought plenty of good news in medical advances, biotech is an industry where failure is part of the game. Here’s a list of medical fails in biotech to learn from this year. Unfortunately, 2016 has not been a good year for pharma, with revenues in the top companies falling, the lowest number […]

December 23, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Dec 2016

Following Eli Lilly’s Failure, what’s Next in Alzheimer’s Treatments?

Hopes for an Alzheimer’s cure took a hit with Eli Lilly’s recent failure, but it’s not over yet. Probiodrug explains the failure and response. Alzheimer’s Disease devastates families and represents one of the largest financial burdens in society. Now the sixth leading cause of death for all age groups, the neurodegenerative disease cost the US […]

December 19, 2016 - 7 minutesmins - By Evelyn Warner

News and Trends 7 Nov 2016

Results from 45% of Clinical Trials are kept Secret

A new transparency study has identified Sanofi, Novartis and GSK as the companies that keep the most clinical trial results unreported. TrialsTracker is a tool developed at the University of Oxford that automatically rates transparency on clinical trials by checking if there are results available in clinicaltrials.gov and PubMed. The results: globally, 45% of data on […]

November 7, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Eli Lilly

Watch Out Eli Lilly: Novo’s Diabetes Drug Ozempic Gets European Approval

Eli Lilly Offers German Biotech up to €1.5Bn to Develop mRNA Cancer Vaccines

Eli Lilly Partners with German Biotech Against Autoimmune Disease

Novo Nordisk’s New Type 2 Diabetes Drug Outperforms Eli Lilly’s

German Biotech Unveils Positive Phase II Results for Alzheimer’s

Bad News for Diabetics: Eli Lilly Abandons French Ultra-Rapid Insulin

The 8 Biggest Biotech Medical Fails of 2016 in Europe

Following Eli Lilly’s Failure, what’s Next in Alzheimer’s Treatments?

Results from 45% of Clinical Trials are kept Secret

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!